Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer

Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer

A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported quality of life without increasing bone pain.
Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?

Unlocking the Sleeper Effect: Can Mechanism-Based Psychological Interventions Transform IBS and UC Outcomes?

The SOMA.GUT-RCT investigated a targeted psychological intervention for IBS and UC. While the primary 3-month endpoint showed no significant symptom reduction compared to standard care, exploratory data revealed significant psychological improvements and a delayed clinical benefit at 12 months, highlighting the potential for integrated care.
Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Causal Insights Into Hidradenitis Suppurativa: Mendelian Randomization Evidence Linking BMI, Inflammatory Bowel Disease, and Smoking

Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemic sclerosis.
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy

Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy

Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-specific differences across populations. Implications for diagnosis, surveillance, and precision therapy are discussed.
Real-time Sepsis Risk Prediction in Acute Gastrointestinal Bleeding: A Validated Dynamic Monitoring Tool That Improves Early Stratification

Real-time Sepsis Risk Prediction in Acute Gastrointestinal Bleeding: A Validated Dynamic Monitoring Tool That Improves Early Stratification

A multicenter Chinese study developed and validated a real-time nomogram that predicts sepsis in acute gastrointestinal bleeding (AGIB) using clinical and laboratory variables; the tool showed strong discrimination (AUCs 0.827–0.884), good calibration, and an online monitoring platform for dynamic alerts.
Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 weeks, supporting further randomized evaluation.